A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

NCT05811481 ·Status: RECRUITING

Donafenib Plus Sintilimab for Advanced HCC

NCT05162352 ·Status: COMPLETED ·Phase: PHASE2

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

NCT05171309 ·Status: UNKNOWN ·Phase: PHASE2

Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma

NCT05609695 ·Status: UNKNOWN

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

NCT06581315 ·Status: RECRUITING ·Phase: NA

Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

NCT05573282 ·Status: RECRUITING

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

NCT06361758 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT06196775 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

NCT05578430 ·Status: UNKNOWN ·Phase: PHASE2

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

NCT05701553 ·Status: RECRUITING

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

NCT06406634 ·Status: RECRUITING ·Phase: PHASE2

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

NCT06609876 ·Status: RECRUITING ·Phase: NA

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT05924997 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

NCT04035876 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

NCT05048017 ·Status: RECRUITING ·Phase: PHASE2

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

NCT06496815 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

NCT04454905 ·Status: UNKNOWN ·Phase: PHASE2

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

NCT04310709 ·Status: COMPLETED ·Phase: PHASE2

Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma

NCT06708650 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

NCT05262959 ·Status: COMPLETED ·Phase: PHASE2

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

NCT05770882 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

NCT04183088 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

NCT04072679 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

NCT06487559 ·Status: RECRUITING ·Phase: PHASE1

An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma

NCT05580328 ·Status: UNKNOWN ·Phase: NA